-one in Australia and one in Canada-
BELLEVILLE, ON, April 16, 2012 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it is sponsoring two major livestock reproduction conferences this year. The Company's Animal Health division is co-sponsoring with Bayer the first International Beef Cattle Genetics Conference, being held in Rockhampton, Queensland, Australia on May 6-7, 2012. Bioniche Animal Health is also a major sponsor of the 17th International Congress on Animal Reproduction, being held in Vancouver, British Columbia, Canada from July 29 - August 2, 2012.
Bayer and Bioniche International Beef Cattle Genetics Conference
Australia's National Beef Exposition is set to take place in May, 2012 in Rockhampton, Queensland, Australia, with more than 75,000 local, interstate and international visitors expected to attend. Leading up to this Exposition is a two-day International Beef Cattle Genetics Conference at Central Queensland University, co-sponsored by Bioniche Animal Health and Bayer.
In keeping with the Beef Australia 2012 theme of "Innovation, Collaboration, Inspiration, Celebration", the Bayer-Bioniche conference will feature numerous internationally recognized experts delivering papers on the latest in beef cattle genetic and genomic research, technology underpinning the developed world's massive cattle-based industries which deliver billions of dollars in annual revenue in Australia alone.
Bioniche signed a partnership agreement in June, 2010 with Bayer Australia Limited, for the exclusive distribution of two cattle reproduction products in Australia, expanding Bioniche's access to the Australian dairy and beef sectors.
Since the signing of the agreement, Bioniche and Bayer have run several field trials in Australia testing Bioniche cattle reproduction products via synchronised, fixed-time artificial insemination (FTAI) programs. Pregnancy rates of between 40-57% (depending upon breed) were achieved after a single insemination. These results demonstrate the benefits of FTAI for better herd management and planning.
International Congress on Animal Reproduction
The International Congress on Animal Reproduction (ICAR) is a non-profit international organization that conducts conferences on animal reproduction. Founded in 1948, ICAR has held a major conference every 4 years in countries throughout the world. This will be the first year that the conference is being held in Canada - in Vancouver, British Columbia - from July 29th to August 2nd. The theme of the conference is animal reproduction, including animal physiology, animal pathology and reproductive technology. This year's conference is titled, "Celebrating the Past and Embracing the Future". Each conference features invited plenary and symposium papers, other contributed papers, workshops, and a trade exhibition. The last ICAR conference was held in Budapest, Hungary in 2008.
It is expected that over 1,000 delegates from more than 70 countries will participate in ICAR 2012. Delegates will include researchers, students and those engaged in the application of the basic science and applied aspects of reproduction. Delegates will be from veterinary practice, academia and the corporate sector.
"These conferences are very important to Bioniche as they are attended by veterinarians and industry representatives from the livestock reproduction business which is core to our product portfolio," said Mr. Andrew Grant, President of Bioniche Animal Health (global). "Our livestock animal business is anchored by a portfolio of reproduction and embryo transfer products that service a highly specialized embryo transfer industry. Roughly half of the Company's production animal product sales occur in North America, with the remainder split evenly across the three major territories of Australasia, Europe/the Middle East, and South America."
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.
Bioniche Animal Health develops, manufactures and markets veterinary biopharmaceutical products worldwide. In North America, it has development, manufacturing and marketing facilities in Belleville, Ontario, Canada, Athens, Georgia, U.S.A. and Pullman, Washington, U.S.A. In Australia, business is conducted from two sites: Sydney, New South Wales, where sales and marketing, customer support and technical service are located; and Armidale, New South Wales, where research, development and manufacturing facilities are located.
Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2011. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097